Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Eswari Vilayur Clear advanced filters

  • In this issue, Vilayur et al. describe the case of a patient with monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia (CLL). Although 'conventional; immunosuppression with cyclophosphamide and prednisone was unsuccessful, two courses of rituximab reversed the clinical manifestations of CLL-associated glomerulopathy, and resulted in complete clearance of the glomerular deposits.

    • Eswari Vilayur
    • Paul Trevillian
    • Mark Walsh
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 5, P: 54-58

  • The prevalence of chronic kidney disease (CKD) is increasing worldwide. The best therapies currently available aim to control blood pressure and maximize renin–angiotensin–aldosterone system blockade but are only partially effective in humans. A number of emerging therapies have shown benefit in animal models of CKD, and some have been tested to a limited extent in humans. This Review examines these emerging pharmacological strategies in the context of diabetic nephropathy, diabetic and nondiabetic CKD and autosomal dominant polycystic kidney disease.

    • Eswari Vilayur
    • David C. H. Harris
    Reviews
    Nature Reviews Nephrology
    Volume: 5, P: 375-383